This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Strange Case Of Lakewood And Opko Health

Whitney Tilson is disclosing shorts right and left these days. Now his third short position in less than a few months happens to be in Opko Health Inc. (OPK - Get Report). Tilson got the idea of shorting Opko from the Robin Hood Conference that took place on November 21-22. At the same conference, Tilson presented his own short attack on Lumber Liquidators Holdings Inc (LL - Get Report), which is is doing well for him so far.

Opko Health

Lakewood is short or long Opko?

Anthony Bozza presented his short thesis on Opko Health Inc. (OPK - Get Report), a pharmaceutical research company that also develops diagnostic tests, at the Robin Hood Conference. We covered what Bozza had to say about the company briefly before and will go into more detail this time. However, what we find more intriguing is that Lakewood initiated a new position in Opko Health in Q3, according to the 13F filing H/T to one of our readers for pointing it out back in November. The hedge fund bought 302,065 shares of Opko’s common stock in that quarter, meaning that Lakewood was long Opko until the end of September. Interestingly, we have also heard that Lakewood has shorted Opko Health before in the first quarter, however we could not confirm this.

Also see: Whitney Tilson Up 5.4% In October; Gains On GMCR, K12 Shorts

In response to this confusion about whether Lakewood is long or short Opko Health Inc. (OPK - Get Report), the hedge fund said that they had never had a net long in Opko Health. Their reason for acquiring a small long position in the company as stated on Seeking Alpha,

“In the case of a stock that may be difficult to borrow like Opko was in September, it is often prudent to ensure your borrow is secure by shorting more than your desired position size and offsetting it partially with a smaller long position in the event the borrow becomes less available. As a hypothetical example, if you desire a $10 million short position, you may decide to short $12 million and offset it with a $2 million long position, thereby maintaining your desired position size $10 million net short exposure while having ample shares available to meet any possible stock borrow recalls that could ever occur i.e., if the shares ever become less available to borrow by short sellers.”

Lakewood further said that it has now discarded its long position as the stock became more easy to borrow, and the fund has maintained its net short position size. Had Lakewood explained its reason to be long, it would have helped in eliminating a lot of confusion.

Interestingly, the hedge fund did not discuss the short position in their Q3 letter, a copy of which was obtained by ValueWalk. The fund discusses at length many other short positions, including Tesla Motors Inc (TSLA - Get Report), Westport Innovations Inc. (WPRT) (WPT), InterOil Corporation (IOC), Rackspace Hosting, Inc. (RAX), Tangoe Inc (TNGO), Geospace Technologies Corp (GEOS), Mellanox Technologies, Ltd. (MLNX - Get Report) TLV:MLNX, Fusion-IO, Inc. (FIO) and Clean Harbors Inc (CLH). However, there is no mention of the controversial stock in question here.

Also see: Whitney Tilson Follows Up Says K12 'VERY High Conviction Short'

The short case for Opko Health

Lakewood’s short case is based on Opko Health Inc. (OPK - Get Report)’s history of making empty promises and under-delivering on forecasts. To back its allegation, the fund says that out of 30 investments/products that Opko has claimed to be working on, 25 have seen delays and disappointments. Lakewood also thinks that the company’s Latin American business is partly worthless and that it cannot account for the bulk of Opko’s revenues, like the company says. Opko’s showcase, a diagnostic test for Alzheimer’s that accounted for most of its net asset value back in 2012, is now an old story. The unique blood test did not give promising results and it appears the company has moved on, writes Lakewood.

Bozza’s presentation on Opko Health criticizes the company’s history of creating hype over small things. He said that one of its acquisitions, Claros Diagnostics, makes one product which doesn’t work. Furthermore, Opko Health Inc. (OPK - Get Report) is unlikely to see any success in its diagnostic test for prostate cancer and there is also no future for Rayaldy, a drug used to treat chronic kidney disease. Lakewood also expressed no confidence in Opko’s CEO Phillip Frost, because of his curious associations with stock promoters and penny stocks that turn out to be fraud. Given all the stated flaws in the company’s business with an overly-swollen market cap of $5 billion, Lakewood sees 75-100% downside in Opko. Lakewood ended their short thesis by adding,

“We believe Opko Health’s shareholders have unknowingly been fed a placebo, a mere sugar pill of insider share purchases, overhyped opportunities and bullish analyst forecasts. The problem of course with a placebo is generally of confidence. As long as people believe in the efficacy of a placebo, it has remarkable powers, but once people realize the supposed wonder drug is just a sugar pill, its powers can suddenly disappear.”

And here’s a fun fact: in Lakewood’s presentation, they mention that Opko Health Inc. (OPK - Get Report) frequently gets bullish reviews from the financial blog, Seeking Alpha. They go on to say that stocks that are highly covered by this blog tend to be volatile and act as day trading vehicles. Whitney Tilson, also short Opko Health, happens to be a popular blogger on Seeking Alpha. To his credit, Tilson has lately only discussed short ideas there. Lakewood Capital also chose Seeking Alpha to disclose their short publicly, where they said,

“Lakewood has never published its research and analysis in a public forum, in this case, we feel compelled to do so as all investors deserve fair access to the research that underscores the cautious view that we have expressed.”

We’re just saying.

See full letter here- Opko-Health-report-Lakewood-Capital-12-11-13.pdf

-By Tabinda Hussain

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IOC $28.03 -3.10%
MLNX $45.86 -3.10%
LL $12.34 -3.10%
OPK $8.27 -2.00%
TSLA $162.60 -7.26%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs